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Objectives: to evaluate if ultrasound contrast-agent infusion could improve duplex-ultrasound imaging of peripheral
arterial disease (PAD) and increase the agreement with digital subtraction arteriography (DSA).
Design: prospective and consecutive study.
Material: of 60 consecutive PAD patients, 15 were found to have an inconclusive duplex-ultrasound scan of the
trifurcation and were included in the study. All 15 patients (53% male) were scheduled for DSA, all being candidates
for vascular surgery due to claudication (n 3, 20%), rest pain (n 5, 33%) and tissue loss (n 7, 47%).
Methods: on the day before DSA, a duplex-ultrasound scan of the trifurcation was performed. If the duplex-ultrasound
scan was found inconclusive, it was repeated during continuous ultrasound contrast-agent infusion. DSA was performed
unaware of the duplex-ultrasound results and served as the gold standard.
Results: after contrast-agent administration, the number of inconclusively diagnosed segments was significantly reduced
by 26 (70%), from 37 to 11(p5 0.001). In 19 segments (73%) contrast-agent infusion changed the diagnosis in accordance
with the DSA (p5 0.05). Values of sensitivity and positive predictive value were improved from 0.20 (0.04±0.62) to 0.47
(0.26±0.69) and 0.50 (0.10±0.91) to 0.80 (0.49±0.93), respectively. Specificity and negative predictive value were
unchanged. Agreement between duplex-ultrasound and DSA were improved from poor (k 0.18 (95% CI: 0±0.82)) to
moderate (k 0.45 (0.17±0.74)) (p 0.44).
Conclusion: ultrasound contrast-agents improve the diagnostic ability of duplex-ultrasound when scanning difficult
arterial segments in patients suffering from PAD.
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Introduction
In most vascular centres, digital subtraction arterio-
graphy (DSA) is the preferred `` gold standard'' for
diagnostic imaging prior to arterial reconstruction,
although invasive and associated with a small but
constant risk of major complications of 2%.1 Within
the last decade, duplex-ultrasound arterial scanning
has increasingly been used in examination of periph-
eral arterial disease (PAD). Diagnostic imaging in PAD
can be obtained both above and below the knee and
comparative studies have demonstrated that the diag-
nostic ability of duplex-ultrasound is similar to that of
digital subtraction arteriography (DSA).2±7 Though
sensitivity and specificity are close to 100%, a small
but not negligible percentage of patients are poorly
imaged with duplex-ultrasound.2,5,8
Duplex-ultrasound of the trifurcation in PAD is
difficult, and suboptimal visualization commonly
occurs ± probably due to the small size and deep
course of the vessels as well as low inflow pressure
in patients with multilevel occlusive disease.
These technical limitations have been challenged by
the introduction of ultrasound contrast-agents, having
the capability to increase the strength of the returning
signal. In the few available clinical studies, ultrasound
contrast-agents were found to increase the signal to
noise ratio from the iliac, femoral, renal and intracra-
nial arteries ± although the clinical impact is largely
uncertain.9±11 No studies yet have compared contrast-
agent enhanced duplex-ultrasound with DSA in
PAD-patients nor evaluated continuous contrast-
agent infusion.
The aim of the present study was to prospecti-
vely assess the augmentation of diagnostic ability
after ultrasound contrast-agent infusion in patients
with PAD, all being possible candidates for arterial
reconstruction.
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Material and Methods
Patients
During a 10-month period, 60 legs of 60 consecutive
patients had a routine duplex-ultrasound scanning of
the lower limb performed due to PAD (SVS-ISCVS
category 3±5).12 Of these, 15 patients had an inconclu-
sive duplex-ultrasound scanning of the trifurcation
and were enrolled in the study. All patients were
possible candidates for elective surgery and sched-
uled as inpatients for a routine arteriography. Patients
characteristics are listed in Table 1.
In order to compare the study-group with the back-
ground PAD-population, a recent published series of
94 PAD-patients served as a reference-group.13 The
local ethical committee approved the study and
informed consent was obtained form each patient.
Colour duplex-ultrasound arterial scanning
The same physician performed all duplex-ultrasound
examinations on the day before arteriography. For
descriptive reasons, the trifurcation was divided into
four individual segments: the tibioperoneal trunk and
the origin (the most proximal first centimetre) of the
three crural arteries ± the anterior tibial artery,
the posterior tibial artery and the peroneal artery. The
examination of the trifurcation was only considered
conclusive if all four segments could be identified ±
either by detection of a colour signal or by identifica-
tion of a vessel-wall if the segment was occluded.
Before and after contrast-agent administration all
four arterial segments were classified as significantly
diseased (diameter reduction 50% and occlusions), non-
significantly diseased (diameter reduction5 50%) or
inconclusive. In order to separate significant from
non-significant stenosis, a peak-systolic velocity ratio
42.5 was used (the peak systolic velocity across the
stenosis divided by the peak systolic velocity just
proximal to the stenosis).14±16 When the examination
of the trifurcation was found to be inconclusive on
the first duplex-ultrasound scanning, an ultrasound
contrast-agent (Levovist1) was administrated and
the trifurcation re-examined.
All patients were scanned resting on the side using
a colour duplex ultrasound system (Elegra, Siemens,
Issaquah, WA, U.S.A.) and a 7.5 MHz linear array
transducer. Velocity measurements were made in
areas where the colour-image suggested velocity
increase or turbulence or when the B-mode image
suggested diameter changes. All velocities were
obtained from the centre-stream of the vessels with
an angel of insonation between 30 and 60.
Ultrasound contrast-agent
Levovist1 (Schering AG, Berlin, Germany) is a
galactose-based echo-enhancing contrast-agent
(99.9% galactose, 0.1% palmitic acid). When mixed
with water, it generates a milky gaseous suspension
of micro-bubbles only a few mm in size (median dia-
meter of 2 mm, 95% smaller than 8 mm).17 After intra-
venous injection, the micro-bubbles are capable of
passing through the lung-capillaries and reaching the
systemic circulation. When Levovist1 is injected intra-
venously, the micro-bubbles act as highly effective
back-scatters of ultrasound, significantly increasing
the strength of the returning signal. Most commonly,
Levovist1 is administrated as a bolus-injection giving
a relative short duration of peak-enhancement of
approximately 1±2 min. In order to overcome this limi-
tation, a bolus of 2 ml Levovist1 (300 mg/ml) was
followed by a continuous infusion (1 ml/min) of
11.5 ml (total dose 4 g) using an automated injector
system (Medrad Pulsar, Medrad Inc., Indianola,
U.S.A.) giving approximately 12±14 min of optimal
enhancement.
Following intravenous injection, the Levovist1
micro-bubbles dissolve in the bloodstream and
galactose is subject to insulin-independent glucose
metabolism, mainly in the liver. Levovist1 is generally
non-toxic, but should logically not be given to patients
suffering form galactosaemia. Levovist1 is hypero-
smotic and should be avoided in patients with critical
cardiac failure and pulmonary fluid retention (NYHA
stage IV). Even after repeated administrations of the
Table 1. Patients characteristics of the study- and reference-
population.
Characteristics Study Reference p value
Median age (range), years 72 (51±87) 71 (41±89) n.s.
Male sex 8 (53%) 65 (68%) n.s.
Ankle blood pressure
(range), mmHg
50 (25±100) 60 (0±170) n.s.
Ankle-brachial pressure
index (range)
0.36
(0.18±0.62)
0.40
(0±1.13)
n.s.
Symptoms
Claudication (SVS/ISCV: 3) 3 (20%) 23 (25%)
Rest pain (SVS/ISCV: 4) 5 (33%) 30 (33%) n.s.1
Tissue loss (SVS/ISCV: 5) 7 (47%) 39 (42%)
Diabetes (type I and II) 6 (40%) 31 (34%) n.s.
End stage renal disease
(in dialysis)
1 (7%) 2 (2%) n.s.
n.s.: Not significant.
1 p-value was calculated for differences in proportions (claudica-
tion/rest pain/tissue loss).
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diagnostic dose at short intervals, there is no risk of
neither acute nor systemic intoxication. No allergic
reactions are described in the available literature.
Digital subtraction arteriography
In all patients the vessels from the aortic bifurcation to
the pedal arteries were visualized using one of two
standard angio-equipments: Integris 3000 (Philips,
Best, The Netherlands) or Angiostar Plus (Siemens,
Forchheim, Germany). Omnipaque 300 mg I/ml
(Nycomed, Oslo, Norway) were used as contrast-
agent. Ipsilateral puncture of the common femoral
artery was performed. After demonstration of the
iliac arteries the 5F catheter was withdrawn to exter-
nal iliac artery in order to visualise the vessels of the
leg and foot in patients with unilateral PAD. In case of
bilateral PAD a standard bolus chase arteriography
was performed. If the infrapopliteal vessels including
the pedal arteries were insufficiently visualised,
selective series were performed. The trifurcation was
classified as described for the ultrasound technique.
Segments were classified as non-diagnostic if no genu-
ine or unnamed collateral vessels could be visualised
due to inadequate contrast-agent opacification (`` con-
trast underfilling''). The radiologist reading the arter-
iogram was unaware of the duplex findings.
Data analysis and statistics
Results obtained by ultrasound and arteriography
were recorded in similar diagrams. The paired-
samples t-test was used to test differences before and
after contrast-agent administration. When appropri-
ate, the chi-squared-test or Fisher's exact test was
used for comparison of categorical data, and the two-
sample t-test for continuous data. Agreement between
duplex and arteriography were compared using the
kappa (k) statistics to analyse the agreement beyond
chance, and a z-test to test the difference between the
agreements. A k-value of 1 represents perfect agree-
ment and a k-value of 0 represents agreement by
purely chance.18 A p-value5 0.05 was considered
significant. Sensitivity and specificity were calculated
by a two-way contingency table and presented with
95%-confidence interval in brackets.
Results
The study group (n 15) was similar to the reference
group with respect to age, sex, and the distribution in
the SVS-ISCV categories (Table 1).
In these 15 patients with inconclusive segments, a
total of 60 arterial segments were available for analy-
sis. All 60 segments were found diagnostically visua-
lized on DSA. After contrast-agent administration, the
number of inconclusively diagnosed segments was
significantly reduced by 26 (70%), from 37 to 11
(p5 0.001) (Fig. 1, Table 2). Of these 26 segments,
contrast-agent administration changed the diagnosis
correctly in 19 segments (73%) and incorrectly in
7 (27%), using arteriography as the gold standard
(p5 0.05) (Fig. 2).
There was disagreement between duplex and
DSA after contrast administration in only seven
segments: five segments were found to be normal on
contrast-enhanced duplex-ultrasound, whereas DSA
indicated occlusion and two segments, considered
occluded on duplex, were normal on DSA (Fig. 2).
Contrast-agent administration did not change the
diagnosis in any segments assessed as conclusive
on the primary non-enhanced duplex-ultrasound
scanning.
Sensitivity and positive predictive value improved
from 0.20 (0.04±0.62) to 0.47 (0.26±0.69) and 0.50
(0.10±0.91) to 0.80 (0.49±0.93), respectively. Specificity
and negative predictive value remained virtually
unchanged (Table 2).
Agreement between duplex-ultrasound and DSA
for the diagnostically visualised segments, was
improved from poor (k 0.18 (95% CI: 0±0.82)) to
moderate (0.45 (0.17±0.74)) following contrast-agent
administration, although this difference was not sig-
nificant (p 0.44) (Table 2).
Fig. 1. The proportion of conclusive/inconclusive duplex scans
before and after ultrasound contrast-agent administration.
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Table 2. Data for the study population (15 patients, 60 segments).
DSA
Disease ÿDisease Inconcl. Total
Before Levovist1 administration
Ultrasound
Disease 1 1 0 2
ÿDisease 4 17 0 21
Inconcl. 16 21 0 37
Total 5 (21) 18 (39) 0 23 (60)
After Levovist1 administration
Ultrasound
Disease 8 2 0 10
ÿDisease 9 30 0 39
Inconcl. 4 7 0 11
Total 17 (21) 32 (39) 0 49 (60)
Results of the conclusive segments only (bold figures)
Duplex-ultrasound Without contrast-agent With contrast-agent p-value
Conclusively diagnosed segments 23 49 0.001
Inconclusively diagnosed segments 37 11 0.001
Sensitivity (95% CI) 0.20 (0.04±0.62) 0.47 (0.26±0.69)
Specificity (95% CI) 0.94 (0.74±0.99) 0.94 (0.80±0.98)
Positive predictive value (95% CI) 0.50 (0.01±0.91) 0.80 (0.49±0.94)
Negative predictive value (95% CI) 0.81 (0.60±0.92) 0.77 (0.62±0.87)
Agreement (k) (95% CI) 0.18 (0±0.82) 0.45 (0.17±0.74) n.s.
Fig. 2. Flow-chart illustrating the effect of contrast-agent administration on primarily inconclusively diagnosed arterial segments.
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The mean examination time, including both duplex-
ultrasound examinations (enhanced and non-enhanced),
preparation of contrast-agent and loading infusion
pump was approximately 30 min. No complications
or side effects were recorded following the contrast-
agent administration.
Discussion
For the first time, we have demonstrated that an
ultrasound contrast-agent (Levovist1) significantly
reduces the number of inconclusive scans in the tri-
furcation ± known as one of the most problematic
arterial segments when visualising PAD. Contrast-
agent administration significantly improves the diag-
nostic ability of duplex-ultrasound in inconclusive
segments with 73%, when using DSA as the gold
standard. Additionally, sensitivity, positive predictive
value and agreement with DSA were improved fol-
lowing contrast-agent administration.
Following ultrasound contrast-agent administra-
tion, five segments originally considered inconclusive
were erroneously classified as normal ± although
occluded on DSA. This phenomenon can be explained
by either a disadvantage of the enhanced ultrasound
technique, or as a known limitation in DSA when
visualising multilevel diseased arteries below the
knee. It's well known when visualising vessels distal
to multiple occlusive lesions, that the resulting low
contrast-agent concentration (`` contrast underfilling'')
can make patent vessels look occluded on arteriogra-
phy.19 Though, DSA was considered representing the
truth, a small proportion of patent runoff vessels
being invisible on DSA has previously been described
when comparing DSA with magnetic resonance arter-
iography (MRA).20 Additionally, DSA of the trifurca-
tion is connected with a moderate interobserver
variation.2 Thus, DSA could be questioned as the
gold standard when visualising vessels below the
knee, especially in patients with multilevel occlusive
disease. In these cases, contrast-agent-enhanced
duplex-ultrasound could serve as a valuable alterna-
tive or supplement to DSA having the possibility to
increase the limb salvage rate by detecting DSA invis-
ible runoff.
When visualising PAD in most vascular regions, the
duration of a single contrast-agent injection is often
too short for an ultrasound examination and therefore
of limited clinical relevance. In the present study, an
infusion-pump was used, giving a relative long period
of stable diagnostic enhancement of 12±14 min.
Moreover, with continuous infusion, blooming and
shadowing in the early phase of the enhancement,
as seen after a single bolus injection, is avoided. Due
to a remote control, continually scanning was
possible independently of infusion start and bolus
administration.
The available literature addressing ultrasound
contrast-agent in PAD is very limited, especially when
evaluating arteries below the knee. In the iliac arteries,
Vogt et al. demonstrated a marginal improvement in
the diagnostic confidence of duplex-ultrasound after a
single injection of Levovist1, using intravascular
ultrasound as the reference.11 A subgroup of a phase
III study from 1993 investigated Levovist1 in PAD
patients using a visual analogue scale, and found the
number of suboptimal duplex scans reduced after
Levovist1 injection.21
Although cost-benefit analysis was not the purpose
of the study, the costs of a single dose (4 g) ultrasound
contrast-agent (Levovist1) were approximately 135$
(1145 Dkr.), being comparable with the cost of iodi-
nated contrast-agent used for a routine DSA. In the
diagnostic workup of PAD, using duplex-ultrasound
as the primary imaging modality, supplementary use
of ultrasound contrast-agent can potentially reduce
the number of patients needing a diagnostic arterio-
graphy. Because duplex-ultrasound, with and without
contrast-agent enhancement, is non-invasive and well
tolerated, no additional costs compared to DSA are
required for post procedural observation and treat-
ment of possible complications. Besides the econo-
mical aspect of replacing some DSA procedures with
contrast-agent enhanced duplex-ultrasound, patients'
discomfort and risk can possibly be reduced as well as
the radioactive exposure to both staff and patients.
Although not addressed in this study, ultrasound
contrast-agents may be beneficial in several vascular
regions besides the trifurcation when arterial insona-
tion is inadequate: e.g. in obese and oedematous
patients being generally difficult visualize due to a
suboptimal signal to noise ratio and in diabetic and
uremic patients with a high attenuation of the ultra-
sound waves due to highly calcified vessels.22 The
high proportions of females in the study-population
could possibly be a result of a sex-linked higher cir-
cumference of the calf. In further studies, factors such
as BMI should be accounted.
In conclusion, ultrasound contrast-agents can
improve the diagnostic ability of duplex-ultrasound
when scanning difficult arterial segments in patients
suffering from PAD. By lowering the number of incon-
clusive duplex scans, ultrasound contrast-agents
have the potential to expand the indications for non-
invasive assessment of PAD. In selected cases,
contrast-enhanced duplex scanning may allow visual-
isation of patent runoff vessels which are invisible on
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arteriography, improving the opportunity for limb
salvage surgery. In the future, ultrasound contrast-
agents should be a more common supplement to the
non-invasive diagnostic armamentarium when evalu-
ating patients with PAD.
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